Poseida Therapeutics Added to NASDAQ Biotechnology Index
News provided by
Share this article
Share this article
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index
® (Nasdaq: NBI). Addition to the NBI will become effective prior to market open on Monday, December 21, 2020.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market
® (Nasdaq
®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The Index is